NEW YORK (GenomeWeb News) – EKF Diagnostics this week said it completed its acquisitions of Selah Genomics and DiaSpect Medical. When the deals were announced last month, EKF said the Selah acquisition comprises an initial consideration of $35.6 million through the issue of new EKF shares and an additional deferred consideration of up to $35 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.